Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19481147 | 1.00 | METAP1 (0.34) | METAP1GABRR1GABBR2GABBR1TSHR | |
| SCHEMBL20963211 | 0.88 | GABRR1 (0.39) | GABRR1GABBR2GABBR1 | |
| SCHEMBL599955 | 0.85 | TSHR (0.40) | METAP1TSHROPRM1 | |
| SCHEMBL1164789 | 0.84 | ALDH1A1 (0.41) | TSHROPRM1SPHK1 | |
| SCHEMBL21767042 | 0.82 | DNM1 (0.42) | TSHROPRM1SPHK1 | |
| SCHEMBL1165559 | 0.80 | SPHK1 (0.48) | TSHROPRM1SPHK1 | |
| SCHEMBL21126665 | 0.80 | — | — | |
| SCHEMBL5933640 | 0.80 | — | — | |
| SCHEMBL5932767 | 0.80 | — | — | |
| SCHEMBL23435739 | 0.79 | METAP1 (0.32) | METAP1GABRR1GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| EP-4289951-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023205451-A1 | CYCLIC PEPTIDES FOR DELIVERING THERAPEUTICS | ENTRADA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2020033129-A1 | REJUVENATION OF CAR T CELL | PURDUE RESEARCH FOUNDATION (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2017139414-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO INC. (KY) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017031427-A1 | COMPOUNDS AND METHODS FOR INHIBITING mTOR | 3-V BIOSCIENCES, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-8263634-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| EP-2492265-A1 | 1,2,4-Thiadiazole Compounds and Pests Controlling Composition Containing the same | Sumitomo Chemical Company, Limited (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | disclosed |
| US-7371746-B2 | 1,2,4-Thiadiazole compounds and pests controlling composition containing the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2008-05-13 | — | — | US | disclosed |
| EP-1765798-A2 | 1,2,4- THIADIAZOLE COMPOUNDS AND PESTS CONTROLLING COMPOSITION CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-20070004722-A1 | 1,2,4-Thiadazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| WO-2005037805-A2 | 1,2,4-THIADIAZOLE COMPOUNDS AND PESTS CONTROLLING COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-28 | — | — | WO | disclosed |
| US-4027037-A | ARTHROPOD METAMORPHOSIS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | GCK, HK1, HK2 | METAP1 1193/4885GABRR1 4035/4885GABBR2 3547/4885 |
| US-20070004722-A1 | 1,2,4-Thiadazole compounds and use thereof | CYP4F3, CYP4B1, CYP4X1 | METAP1 3177/4885GABRR1 3263/4885GABBR2 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.